Uy Ear
Stock Analyst at Mizuho
(2.83)
# 1,882
Out of 4,981 analysts
66
Total ratings
38.46%
Success rate
11.21%
Average return
Main Sectors:
Stocks Rated by Uy Ear
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ACAD ACADIA Pharmaceuticals | Maintains: Neutral | $23 → $24 | $24.67 | -2.72% | 13 | Aug 7, 2025 | |
| MBX MBX Biosciences | Initiates: Outperform | $38 | $10.87 | +249.59% | 1 | Aug 5, 2025 | |
| SRPT Sarepta Therapeutics | Downgrades: Neutral | $40 → $14 | $17.47 | -19.86% | 8 | Jul 21, 2025 | |
| TECX Tectonic Therapeutic | Maintains: Outperform | $51 → $85 | $16.59 | +412.36% | 2 | May 15, 2025 | |
| ARQT Arcutis Biotherapeutics | Maintains: Outperform | $20 → $21 | $16.93 | +24.04% | 14 | Feb 26, 2025 | |
| QURE uniQure | Maintains: Neutral | $7 → $20 | $14.84 | +34.82% | 4 | Dec 19, 2024 | |
| RLMD Relmada Therapeutics | Downgrades: Neutral | $23 → $1 | $1.67 | -40.12% | 1 | Dec 5, 2024 | |
| ALKS Alkermes | Maintains: Outperform | $35 → $40 | $26.52 | +50.83% | 5 | Nov 13, 2024 | |
| RNAC Cartesian Therapeutics | Initiates: Buy | $40 | $9.79 | +308.58% | 1 | May 24, 2024 | |
| EOLS Evolus | Maintains: Buy | $20 → $23 | $6.63 | +246.91% | 3 | Mar 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $116 → $140 | $140.44 | -0.31% | 10 | Feb 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $36 → $40 | $177.40 | -77.45% | 1 | Jun 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $10 | $1.91 | +423.56% | 1 | Mar 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $5 → $3 | $1.20 | +150.00% | 2 | Mar 1, 2023 |
ACADIA Pharmaceuticals
Aug 7, 2025
Maintains: Neutral
Price Target: $23 → $24
Current: $24.67
Upside: -2.72%
MBX Biosciences
Aug 5, 2025
Initiates: Outperform
Price Target: $38
Current: $10.87
Upside: +249.59%
Sarepta Therapeutics
Jul 21, 2025
Downgrades: Neutral
Price Target: $40 → $14
Current: $17.47
Upside: -19.86%
Tectonic Therapeutic
May 15, 2025
Maintains: Outperform
Price Target: $51 → $85
Current: $16.59
Upside: +412.36%
Arcutis Biotherapeutics
Feb 26, 2025
Maintains: Outperform
Price Target: $20 → $21
Current: $16.93
Upside: +24.04%
uniQure
Dec 19, 2024
Maintains: Neutral
Price Target: $7 → $20
Current: $14.84
Upside: +34.82%
Relmada Therapeutics
Dec 5, 2024
Downgrades: Neutral
Price Target: $23 → $1
Current: $1.67
Upside: -40.12%
Alkermes
Nov 13, 2024
Maintains: Outperform
Price Target: $35 → $40
Current: $26.52
Upside: +50.83%
Cartesian Therapeutics
May 24, 2024
Initiates: Buy
Price Target: $40
Current: $9.79
Upside: +308.58%
Evolus
Mar 8, 2024
Maintains: Buy
Price Target: $20 → $23
Current: $6.63
Upside: +246.91%
Feb 8, 2024
Maintains: Neutral
Price Target: $116 → $140
Current: $140.44
Upside: -0.31%
Jun 7, 2023
Maintains: Buy
Price Target: $36 → $40
Current: $177.40
Upside: -77.45%
Mar 17, 2023
Reiterates: Buy
Price Target: $10
Current: $1.91
Upside: +423.56%
Mar 1, 2023
Maintains: Buy
Price Target: $5 → $3
Current: $1.20
Upside: +150.00%